asininityandbeyond (@asininitybeyond) profile picture
Joined March 2018
Replying to @tom_the_bomb__
Dep Chair + new AuditCo chair appointed, both biotech veterans. Latter officially stepping up on 30th September - the day the Capital Access Window opened Not unreasonable to assume a partner would want #AVCT to beef up governance if handing over cash + taking an equity position
2
3
31
3,423
Replying to @JStonker
It’s a good observation. Worth thinking broader than generic placing and consider other fundraising mechanisms which might include an equity component. Commercial deal with equity component and cash? For “Faridoxorubicin, pending partnering” per the interims. 1/2
2
1
2
1,486
In other #AVCT news ⬇️ Surely nodding at more than a hint of efficacy in AVA6103? The key clinical activity and, therefore, validation in H1 being the FOCUS trial. Doesn’t make sense for this comment to relate to A6K, IMO. Many have assumed AVA6103 efficacy, now confirmed? 2/2
25
1,254
Back to 6103, the fact the below statement precedes the pre-clinical efficacy comparison with Enhertu, says it all really: preclinical PK = modelled deep and prolonged partial responses ➡️ observed patient PK = patient anti tumour activity Read between the lines 2/2 #AVCT
1
28
1,794
Astonishing safety comparisons with Enhertu, which did $1.4bn revenue in Q1 26. The usual mention partnering, inflection points etc. We are talking serious, scaled deals given what is in the data. “Pipeline expansion”… left field… watch this space IMO 1/2 #AVCT
1
6
56
3,286
Vesting conditions - 6103 readout makes sense. 6207 candidate selection has been signposted Not sure if intended to be sequential but, if so, new IND filing between the above is curious. It would logically follow the last item if 6207 related Something left field in play? #AVCT
1
44
2,899
AVA6000 patient population is getting increasingly meaningful Acknowledgment of this full ‘n’ group further supports my view that accelerated pathways for SGC (and maybe others) leverage the strong safety of the full trial, beyond just indication subsets Very positive IMO #AVCT
1
3
44
2,484
Been busy with the day job recently but lots of positives coming from #AVCT now. This CEO statement is incredible. Confidence abounds + much to parse from these 4 paragraphs alone! Growing IP, rapid development, multiple commercial opps, broadening application of the tech.1/3
1
5
61
2,422
$LLY acquires CAR-T myeloma focussed Kelonia for up to $7bn. $3.5bn u/f + rest depends on milestones Lead asset Ph1, <40 pts dosed Platform tech ➡️ immediate read across to preCISION from Jake “we want the next Enhertu” Van Naarden - simplicity, turn-key, broad potential #AVCT
3
4
1
48
6,577
Revolution raises $2bn. Upsized 100% vs initial target of $1bn - placing shares issued at $142. Little to no discount. Good data opens so many doors. #AVCT
“Daraxonrasib achieved OS of 13.2 months compared to 6.7 months for chemotherapy.” - BioSpace “PFS doesn’t matter”, “Pharma only wants cures” narrative going right out the window. Giving patients more time really matters. Expect updated AVA6000 data this Q really shines. #AVCT
3
31
3,223